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Methods: It has been set a prospective study to assess control pain and
functional performance in a group of patients affected by hip arthritis,
before and after viscosupplementation. From May 2005 to September 2009
we performed an intra articular inﬁltration into the hip of 207 patients
(108 male, 99 female), mean age 67,8 (range 40-83). Each patient re-
ceived under ﬂuoroscopic guidance one injection of highly puriﬁed sodium
hyaluronate derived from bacterial fermentation, containing 75 mg of
sodium hyaluronate per 3-ml syringe. The inclusion criteria were: hip pain,
radiographic evidence of arthritis with the articular rima at least partly
conserved, full range of motion of affected hip. All patients were evaluated
using BPI score, VAS score and Harris Hip score, pre-inﬁltration, after
three, six and twelve months after treatment. The categorical data were
summarized in terms of frequency and percentage. Continuous data where
analyzed in terms of mean, standard deviations, Student’s test. 150 patients
out of 207 were studied at six months follow-up, 121 patients out of 207
were studied at one year follow-up.
Results: Mean VAS scores before inﬁltration and at 1 year follow-up were
5.6 (range 10-6, SD 2,01) and 3.33 (range 10-3, SD 2.99) respectively
(p<0,05). Mean HHS were 44.2 (range 24-66, SD 10.4) and 76.5 (range
32-81, SD 16.4) respectively (p<0,05). Mean BPI Interference score were
27,38± (range 16-53, SD 17,68) and 14,35 (range 8-34, SD 12,60) respec-
tively (p<0,05). Fifty three patients (43%) reported at least 50% of pain
relief of pain at 6 months follow-up. Each item of BPI showed a decrease
of pain interference during daily activity. The decrease was statistically
signiﬁcant for all items (p<0,05). Particularly decreasing was observed for
pain interference with sleep (from 4,09, SD 3,15 pre inﬁltration to 1,27,
SD 1,36 at 1 year follow-up), mood (from 4,40, SD 3,17 pre inﬁltration to
2,04, SD 2,37 at 1 year follow-up), enjoy (from 3,21, SD 3,46 pre inﬁltration
to 1,27, SD 2,10 at 1 year follow-up). No local side effects or systemic
complications was observed in our series.
Conclusions: Our data show that viscosupplementation is a promising
approach for hip osteoarthritis, providing beneﬁcial effects in a long-term
follow up. The results demonstrated that it is possible to delay replacement
of the arthritic hip, but above all that hip pain could be eliminated in
patients clinically and radiographically at the limit of the indication for
surgical treatment.
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HYALURONIC ACID MANAGEMENT OF KNEE OSTEOARTHRITIS: IMPACT
ON PAIN
C. Taieb Sr.1, R. Dreiser Sr.2, J. Pibourdin Sr.3, N. Rahhali Jr.1
1PFSA, Boulogne Billancourt, France; 2Rhumatologist, Paris, France; 3PFS,
Castres, France
Purpose: Chronic pain or chronic pain syndrome is deﬁned as a mul-
tidimensional syndrome, when the pain expressed leads to a signiﬁcant
and progressive deterioration in the patient’s functional and relational
capacities. Knee osteoarthritis is a real public health problem. According to
data from the Framingham study, its prevalence is estimated to be 6.1% of
adults over the age of 30. This prevalence increases with age, to more than
40% after the age of 75. Knee osteoarthritis is generally not life-threatening,
but it does signiﬁcantly affect the daily lives of patients who have it and
incurs very high costs for the community
Methods: Pragmatic, longitudinal and prospective follow-up carried out
by rheumatologists in the context of their daily professional activities;
the investigator does not change the prescription or management habits.
The objective is to observe, under actual conditions of use, the pain
effect obtained, in the context of management of knee osteoarthritis, using
hyaluronic acid (injectable route).
Results: 191 patients are treated with hyaluronic acid. The average age is
64.72 years (±7.34). Average pain during activities of daily living (ADL) was
measured by means of a visual analogue scale (VAS). It is 50.12±19.32 at
inclusion.
At 6 months, this same average pain measured under the same conditions is
36.95±25.10. A third measurement at 12 months situates it at 38.10±23.19.
Pain during ADL is signiﬁcantly reduced between inclusion and month 6
(p=0.0023) and between inclusion and month 12 (p=0.0012).
With regard to pain measured at rest, it was also measured at inclusion,
at 6 and 12 months, by means of VAS. There is a signiﬁcant reduction in
pain at rest between inclusion and 6 months (p=0.0004) and the reduction
between inclusion and month 12 is also signiﬁcant (p=0.0007). At inclusion,
6 and 12 months, the average pain observed is 33.48±22.45, 19.90±19.88
and 21.64±22.94, respectively.
Conclusions: Our study, which assesses the effect on pain obtained in
the context of management of subjects with knee osteoarthritis, using
hyaluronic acid, showed a reduction in pain during ADL. This reduction
in pain, which is signiﬁcant at 6 months, then perpetuated at 12 months,
shows the relevance of the treatment protocol used by the doctors.
Therapy – Non-Pharmacologic
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EFFECTS OF ORAL ADMINISTRATION OF HYAL-JOINT® IN 17 DAY RAT
DEVELOPING TYPE II COLLAGEN ARTHRITIS
V. Castillo1, A.M. Bendele2, K. Li3, D. Martinez-Puig1 , S.M. Turner3,
C. Chetrit1
1BIOIBERICA S.A., PALAFOLLS, Spain; 2BolderPATH Inc., Boulder, CO; 3KineMed
Inc., Emeryville, CA
Purpose: To determine the effect of Hyal-Joint® administered by twice
daily oral dosing on inﬂammation, cartilage destruction, bone resorption
and synthesis of hyaluronic acid (HA) in synovial ﬂuid (SF) that occurs in
developing type II collagen arthritis in rats.
Methods: Twenty-four female Lewis rats weighing 136-154 g were used
in this study. Rats with developing type II collagen arthritis (n=20) were
treated orally twice daily on days 0-16 of the study with vehicle (H2O;
disease control; n=10) or Hyal-Joint® (7.5 mg, BID; n=10). They were
anesthesized with isoﬂurane and given collagen injection on day 0 and
6. Nonimmunized rats (normal; n=4) were used as normal controls. All
animals received deuterium oxide (2H2O) exposure from day 16-17 to bring
the animal’s body water to a 5% water isotopic enrichment of deuterium.
Animals were terminated on study day 17. Livers, spleen and thymus were
also collected, trimmed of extraneous tissue and weighed.
Eﬃcacy evaluation was based on animal body weights, ankle diameter
expressed as area under the curve (AUC), histopathologic evaluation of
ankles and knees. Isotopic analysis of lavage samples allowed to measure
SF volumes, HA concentration and absolute HA synthesis rate in knee SF.
Results: Body weight gain was signiﬁcantly increased toward normal
for rats treated with Hyal-Joint® (24% increase) as compared to disease
controls. Ankle diameter AUC were not signiﬁcantly reduced (14%; P=0.15)
for rats treated with Hyal-Joint® as compared to disease controls. Relative
liver, thymus and spleen weights for rats treated with Hyal-Joint® were
similar to those showed by normal rats (3.559 vs. 3.583 g, P=0.80; 0.239
vs. 0.222 g, P=0.146; and 0.199 vs. 0.220 g, P=0.191; respectively), which
conﬁrmed Hyal-Joint® safety. Individual ankle and knee histopathology
parameters (inﬂammation, pannus, cartilage destruction, bone resorption)
are showed in Figures 1 and 2, respectively. Summed histopathology scores
were signiﬁcantly reduced in ankle (17%, P < 0.05) and strongly reduced in
knee (51%,P<0.01) toward normal for rats Hyal-Joint® treated
as compared to disease controls.
Collagen-induced arthritis led to a signiﬁcant increase in knee synovial ﬂuid
volume in both vehicle and Hyal-Joint® treated rats, being less pronounced
in the second. HA concentration decreased 33% with disease controls, while
maintained similar to normal values in Hyal-Joint® group. In normal rats,
absolute synthesis rate of HA into the synovial ﬂuid was 0.43 μg/h. Disease
Figure 1
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Figure 2
controls increased this rate to 0.61 μg/h, but Hyal-Joint® treated rats kept
the value of normal rats (0.43 μg/h new HA).
Conclusions: Our results suggest that the use of Hyal-Joint® for the
management of developing type II collagen arthritis in rats is safe and
effective, having beneﬁcial effects on the histopathology parameters in
ankles and knees. Analysis of synovial ﬂuid lavages indicates Hyal-Joint®
reduces absolute synthesis rate of HA into synovial ﬂuid of arthritic animals
to normal levels.
546
CHONDROPROTECTIVE ACTIVITY OF A FORMULATION THAT INCLUDES
MANNOSAMINE
A. Torrent1, R. Ruhí1, A. Arañó2, L. Pérez2, B. van El3
1R&D Joint Care Dept, BIOIBERICA S.A., Palafolls (Barcelona), Spain;
2Pharmacodinamics Dept, Harlan Lab., Santa Perpètua de Mogoda (Barcelona),
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Purpose: To evaluate the potential anti-arthritic activity of a formulation
that includes mannosamine hydrochloride (Mann) and chondroitin sul-
phate (CS) in an in vitro chondrocyte model and in an animal model of
osteoarthritis (OA) induced by meniscectomy.
Mann is an epimer of the natural Glucosamine Hydrochloride (Glu) and a
constituent of bacterial cell walls and is involved in a range of metabolic
processes. It is used as a probiotic in dietary supplements and functional
foods (Lactobacillus plantarum, Bacillus subtilis and Bacillus licheniformis).
Methods: The chondroprotective activity of a formulation based on Mann
+ CS (60 mg/kg/day + 95 mg/kg/day) was tested using a guinea pig model
of OA induced by partial medial meniscectomy. The following treatment
groups were established: blank control group, operated control group, CS
group (95 mg/kg/day), Mann groups (60 and 120 mg/kg/day) and CS +
Mann (95 +60 mg/kg/day). The administration of the corresponding oral
treatments (gastric gavage) was started the day after the surgery. The blank
control and operated control group only received water for injection. The
treatments were administered once a day for 70 days. After this period,
the animals were sacriﬁced by anaesthetic overdose. The femorotibial
joint of the right rear leg was removed. Histology was performed by a
pathologist, in a blind manner, after staining with Hematoxilin-Eosin and
Saffranin-O-Fast Green (or Toluidin Blue). The severity of the OA was
evaluated by the modiﬁed histological/histochemical scale of Mankin et al
(1971). The statistical evaluation between the different groups was carried
out by means of the Mann-Whitney U test.
An in vitro study was performed using bovine chondrocytes cultured in
alginate beads (n=4) in order to compare the activity of a mixture of
Glu+CS versus Mann+CS on extracellular matrix degradation and apoptosis.
Effects on apoptosis were determined by measuring Caspase-3/Caspase-7
activity after a three days of exposure to TNF-α. Effects on degradation
were determined by measuring Metalloprotease activity (MMP activity)
after stimulation with IL-1β for 48 hours followed by APMA activation.
MMP activity was quantiﬁed using a ﬂuorogenic MMP substrate.
Results: In the experimental conditions of the in vivo study, we found that
there were no statistically signiﬁcant differences between the operated
group and the group treated with Mann. The group treated with CS showed
improvement when compared to the operated group, but without statisti-
cal signiﬁcance. In the group treated with the CS and Mann combination,
statistically signiﬁcant improvements were achieved when compared to
the operated group (p<0.05).
The in vitro assays showed that Mann + CS leads to a statistically signiﬁcant
(p<0.05) reduction of apoptosis at medium and high concentrations and
also a reduction in the MMP activity at low and high concentrations. These
effects were not observed in the comparative mixture Glu + CS.
Conclusions: The eﬃcacy study in guinea pig indicates that there is a syner-
gic effect between Mann and CS when they are administered together. The
in vitro studies suggest that the combination Mannosamine Hydrochloride
and Chondroitin sulphate may have a higher chondroprotective activity
than the already marketed formulation of Glucosamine Hydrochloride and
Chondroitin Sulphate.
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A COMBINATION OF A SPECIFIC COLLAGEN HYDROLYSATE WITH A
REFINED ROSE HIP EXTRACT HAS A POSITIVE EFFECT ON THE EXTRA
CELLULAR MATRIX MAINTENANCE OF CARTILAGE CELLS
M. Schunck, S. Oesser
Collagen Res. Inst., Kiel, Germany
Purpose: Experimental studies have demonstrated a stimulatory impact of
collagen hydrolysate on the biosynthesis of cartilage tissue. In addition,
rose hip extracts are described for an anti-inﬂammatory potential.
Aim of the present study was to investigate the inﬂuence of a combination
of both collagen hydrolysate and a rose hip extract in order to determine
the stimulatory and anti-inﬂammatory eﬃcacy on the matrix synthesis of
articular cartilage cells.
Methods: For the investigations a combination of a speciﬁc collagen hy-
drolysate (Fortigel™, GELITA AG, Germany) and a processed aqueous rose
hip extract (nutriﬁn™ motion, Finzelberg, Germany) was used.
Mature articular chondrocytes were isolated from cartilage tissue and the
cells were cultivated in cell culture medium at 37°C under oxygen reduced
conditions (5% O2).
Three days after cell preparation chondrocytes were treated with a combi-
nation of 0.5 mg/ml FORTIGEL™ and 0.05 mg/ml nutriﬁn™ motion.
At the end of the observation period the collagen and proteoglycan biosyn-
thesis of the chondrocytes was quantiﬁed and the results were compared
to the corresponding data of the untreated control cells. To conﬁrm the
stimulatory effect on matrix macromolecule synthesis mRNA expression of
aggrecan and type II collagen was determined.
Moreover, the inhibitory effect of the FORTIGEL™/nutriﬁn™ motion com-
bination on inﬂammatory cytokines (TNFα, IL-6) and matrix degradation
(MMP-1, MMP-13) were tested.
Results: The supplementation of a FORTIGEL™/nutriﬁn™ motion combi-
nation led to a statistically signiﬁcant (p<0.05) stimulation of the extra
cellular matrix synthesis of articular chondrocytes. Type II collagen and
aggrecan biosynthesis was increased by more than 45% in comparison to
the untreated control cells.
Moreover, an anti-inﬂammatory effect as well as an inhibitory impact on
MMP-1 and MMP-13 expression could be observed after FORTIGEL™ and
nutriﬁn™ motion administration compared to the untreated chondrocytes.
Conclusions: The results indicate the eﬃcacy of FORTIGEL™ and nutriﬁn™
motion to stimulate extra cellular matrix biosynthesis and to decrease
inﬂammatory and catabolic processes. These data suggested that especially
a combination of both substances seems to be of particular therapeutic
relevance in the treatment and prevention of osteoarthritis.
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EVALUATION OF THE ADHESION TO THE EULAR AND OARSI
RECOMMENDATIONS FOR THE TREATMENT OF KNEE AND HIP
OSTEOARTHRITIS IN CURRENT PRACTICE
D. Van Linthoudt
Hôpital neuchâtelois, La Chaux-de-Fonds, Switzerland
Purpose: The aim of this study was to evaluate, in real life, the acceptance
of the EULAR and OARSI recommendations for the treatment of knee and
hip osteoarthritis (OA) in the two districts of the Neuchâtel Mountains.
Methods: In March 2008, a questionnaire was sent to all the general
practitioners (GP = 23), internists (IM = 22), orthopedic surgeons (ORTHO
= 8) and rheumatologists (RHEUMATO = 3) of the districts of Le Locle
